Viatris Settles Lawsuit Over 'Immortal' Cells, Resolving Legal Risk
VTRS has more than doubled off its 52-week low of $6.85 on light trading volume (0.3× avg).
Summary
Viatris has settled a lawsuit brought by the family of Henrietta Lacks, which alleged the unauthorized use of her 'immortal' cells in the development and testing of certain drugs. While the settlement details are confidential, this resolution removes a specific legal and reputational overhang for the company. The lawsuit had sought profits from the commercialization of the HeLa cell line for drugs like Denavir and Mylan-Mirtazapine. Resolving this claim reduces uncertainty and potential future liabilities, which is generally viewed as a positive development for investors.
At the time of this announcement, VTRS was trading at $13.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $6.85 to $16.47. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.